Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378041%3A_____%2F21%3A00551982" target="_blank" >RIV/68378041:_____/21:00551982 - isvavai.cz</a>

Alternative codes found

RIV/68378050:_____/21:00551982 RIV/00064190:_____/21:N0000028 RIV/00216208:11120/21:43922157 RIV/00216208:11140/21:10430998 RIV/00216208:11110/21:10430998

Result on the web

<a href="https://www.frontiersin.org/articles/10.3389/fonc.2021.702258/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fonc.2021.702258/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fonc.2021.702258" target="_blank" >10.3389/fonc.2021.702258</a>

Result language

angličtina

Original language name

Analysis of MicroRNA Expression Changes During the Course of Therapy In Rectal Cancer Patients

Original language description

MicroRNAs (miRNAs) regulate gene expression in a tissue-specific manner. However, little is known about the miRNA expression changes induced by the therapy in rectal cancer (RC) patients. We evaluated miRNA expression levels before and after therapy and identified specific miRNA signatures reflecting disease course and treatment responses of RC patients. First, miRNA expression levels were assessed by next-generation sequencing in two plasma samplings (at the time of diagnosis and a year after) from 20 RC patients. MiR-122-5p and miR-142-5p were classified for subsequent validation in plasma and plasma extracellular vesicles (EVs) on an independent group of RC patients (n=107). Due to the intrinsic high differences in miRNA expression levels between samplings, cancer-free individuals (n=51) were included in the validation phase to determine the baseline expression levels of the selected miRNAs. Expression levels of these miRNAs were significantly different between RC patients and controls (for all p <0.001). A year after diagnosis, miRNA expression profiles were significantly modified in patients responding to treatment and were no longer different from those measured in cancer-free individuals. On the other hand, patients not responding to therapy maintained low expression levels in their second sampling (miR-122-5p: plasma: p=0.05, EVs: p=0.007, miR-142-5p: plasma: p=0.008). Besides, overexpression of miR-122-5p and miR-142-5p in RC cell lines inhibited cell growth and survival. This study provides novel evidence that circulating miR-122-5p and miR-142-5p have a high potential for RC screening and early detection as well as for the assessment of patients' outcomes and the effectiveness of treatment schedule.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

10603 - Genetics and heredity (medical genetics to be 3)

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in Oncology

ISSN

2234-943X

e-ISSN

2234-943X

Volume of the periodical

11

Issue of the periodical within the volume

sep

Country of publishing house

CH - SWITZERLAND

Number of pages

12

Pages from-to

702258

UT code for WoS article

000696785600001

EID of the result in the Scopus database

2-s2.0-85115164870